CommercialCoverageHigh impact
Artificial Cervical Intervertebral Disc 7.01.80
Excellus BlueCross BlueShield·Orthopedics, Neurosurgery·Bone & Joints (Orthopedic)
Effective date
Oct 15, 2025
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield has updated their medical policy for artificial cervical intervertebral disc procedures, establishing detailed coverage criteria for both radiculopathy and myelopathy cases, including specific requirements for patient age (18-60), FDA approval verification, conservative treatment failures, and comprehensive documentation requirements.
Action Required
By October 15, 2025: Prior authorization team must update criteria checklists to include all specified requirements: patient age 18-60, skeletal maturity, FDA device approval verification, C3-C7 level restrictions, single or contiguous two-level limitation, documentation of failed conservative treatments (minimum 6 weeks each for 2+ treatments), absence of cervical instability, concordant MRI/CT findings, and exclusion of unmanaged behavioral health disorders. Update encounter forms to prompt providers for complete symptom documentation and physical exam findings. Create separate workflows for radiculopathy vs myelopathy cases and adjacent segment disease scenarios.